2 active not recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 3 Phase 3, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Malignant Carcinoid Syndrome: new trials by email Literature Review of Malignant Carcinoid Syndrome trials Research Report on Malignant Carcinoid Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CardioNETPOL National Registry of Carcinoid Heart Disease Observational Registry of Carcinoid Heart Disease - Carcinoid Heart Disease, Neuroendocrine Tumors | Not yet recruiting | National Institute of Cardiology, Warsaw, Poland | 120 | 2026-06-01 | 2026-03-04 | |
| Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease Transcatheter Tricuspid Valved Stent Graft - Tricuspid Regurgitation, Tricuspid Valve Disease | Not applicable | Active not recruiting | Queen Mary University of London | 15 | 2022-04-06 | 2026-05-08 |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Lutathera - Carcinoid Heart Disease, Carcinoid Syndrome | Phase 2 | Unknown | King's College Hospital NHS Trust | 20 | 2020-10-01 | 2020-08-04 |
| Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Telotristat Ethyl, Lanreotide - Small Intestinal NET, Carcinoid Heart Disease | Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2020-04-01 | 2020-02-05 | |
| Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors Study of the occurrence of Carcinoid Heart Disease - Carcinoid Heart Disease | Active not recruiting | Hospices Civils de Lyon | 670 | 2018-04-16 | 2024-12-03 | |
| Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Octreotide, Placebo, Everolimus - Carcinoid Tumor, Malignant Carcinoid Syndrome | Phase 3 | Completed | Novartis Pharmaceuticals | 429 | 2006-12-01 | 2014-11-21 |
| Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue) - Malignant Carcinoid Syndrome | Phase 3 | Terminated | Ipsen | 4 | 2004-07-01 | 2020-04-30 |
Carcinoid Heart Disease (5) · Serotonin Syndrome (5) · Carcinoid Tumor (3) · Carcinoma (1) · Heart Failure (1) · Heart Valve Diseases (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Tricuspid Valve Insufficiency (1)
Adenocarcinoma (7) · Neoplasms by Histologic Type (7) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Glandular and Epithelial (7) · Neoplasms, Nerve Tissue (7) · Neuroectodermal Tumors (7) · Carcinoma (6) · Neoplasms (6) · Neuroendocrine Tumors (6) · Cardiovascular Diseases (5) · Chemically-Induced Disorders (5) · Drug-Related Side Effects and Adverse Reactions (5) · Heart Diseases (5) · Carcinoid Tumor (4)
Everolimus (1) · Octreotide (1) · Receptor-Like Protein Tyrosine Phosphatases, Class 2 (1) · lanreotide (1) · lutetium Lu 177 dotatate (1) · telotristat ethyl (1)
European Organisation for Research and Treatment of Cancer - EORTC (1) · Hospices Civils de Lyon (1) · Ipsen (1) · King's College Hospital NHS Trust (1) · National Institute of Cardiology, Warsaw, Poland (1) · Novartis Pharmaceuticals (1) · Queen Mary University of London (1)
France (2) · United Kingdom (2) · United States (2) · Australia (1) · Belgium (1) · Canada (1) · Czechia (1) · Finland (1) · Germany (1) · Greece (1) · Italy (1) · Netherlands (1) · Poland (1) · Slovakia (1) · Spain (1)
Andreas Baumbach (1) · Angela Lamarca (1) · Juan Valle (1)
PMID 22119496, PMID 23187897, PMID 28444114
2004 (1)